CL2011002103A1 - Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4. - Google Patents

Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4.

Info

Publication number
CL2011002103A1
CL2011002103A1 CL2011002103A CL2011002103A CL2011002103A1 CL 2011002103 A1 CL2011002103 A1 CL 2011002103A1 CL 2011002103 A CL2011002103 A CL 2011002103A CL 2011002103 A CL2011002103 A CL 2011002103A CL 2011002103 A1 CL2011002103 A1 CL 2011002103A1
Authority
CL
Chile
Prior art keywords
indicated
combination
pharmaceutical composition
indazole
treat
Prior art date
Application number
CL2011002103A
Other languages
English (en)
Inventor
Nigel James Parr
Panayiotis Alexandrou Procopiou
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Timothy John Ritchie
Michael David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2011002103A1 publication Critical patent/CL2011002103A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UN COMPUESTO DE FORMULA (I) O UNA SAL DEL MISMO DONDE N, R1, R2, R3, R4, R5 YR6 SON COMO SE DEFINEN EN EL PLIEGO DE REIVINDICACIONES; COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHO COMPUESTO; UNA COMBINACIÓN DE PRODUCTO FARMACÉUTICO QUE COMPRENDE DICHO COMPUESTO; USO DE DICHO COMPUESTO PARA PREPARAR UN MEDICAMENTO ÚTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD o AFECCIÓN PARA LA QUE ESTA INDICADO UN ANTAGONISTA DEL RECEPTOR CCR4; PROCEDIMIENTO PARA LA PREPARACIÓN DE DICHO COMPUESTO; Y COMPUESTO INTERMEDIARIO.
CL2011002103A 2009-02-26 2011-08-26 Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4. CL2011002103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26

Publications (1)

Publication Number Publication Date
CL2011002103A1 true CL2011002103A1 (es) 2012-02-24

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002103A CL2011002103A1 (es) 2009-02-26 2011-08-26 Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4.

Country Status (30)

Country Link
US (3) US8304446B2 (es)
EP (1) EP2401270B1 (es)
JP (1) JP5520969B2 (es)
KR (1) KR20110128896A (es)
CN (1) CN102388039B (es)
AR (1) AR075594A1 (es)
AU (2) AU2010217629A1 (es)
BR (1) BRPI1013396A2 (es)
CA (1) CA2753337A1 (es)
CL (1) CL2011002103A1 (es)
CO (1) CO6420342A2 (es)
DK (1) DK2401270T3 (es)
DO (1) DOP2011000272A (es)
EA (1) EA021740B1 (es)
ES (1) ES2439773T3 (es)
HR (1) HRP20131174T1 (es)
IL (1) IL214655A0 (es)
MA (1) MA33132B1 (es)
MX (1) MX2011008972A (es)
NZ (1) NZ594641A (es)
PE (1) PE20120307A1 (es)
PL (1) PL2401270T3 (es)
PT (1) PT2401270E (es)
RS (1) RS53133B (es)
SG (1) SG173768A1 (es)
SI (1) SI2401270T1 (es)
SM (1) SMT201400001B (es)
TW (1) TW201041879A (es)
UY (1) UY32464A (es)
WO (1) WO2010097395A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575816B2 (ja) 1988-06-13 1997-01-29 田中貴金属工業株式会社 粉末等の送り方法
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
EP2401277A1 (en) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (en) * 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
PL3490565T3 (pl) 2016-07-29 2022-09-26 Rapt Therapeutics, Inc. Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
WO2018049271A1 (en) 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (en) 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
JP7090639B2 (ja) * 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN110028501B (zh) * 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
AU2019212478C1 (en) 2018-01-26 2023-11-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
CN119585256A (zh) 2022-04-06 2025-03-07 拉普特医疗公司 趋化因子受体调节剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
PL376789A1 (pl) * 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
SMT201400001B (it) 2014-03-07
DK2401270T3 (da) 2014-01-13
TW201041879A (en) 2010-12-01
EA201190142A1 (ru) 2012-05-30
NZ594641A (en) 2013-03-28
DOP2011000272A (es) 2011-12-31
JP2012518673A (ja) 2012-08-16
EP2401270A1 (en) 2012-01-04
US8507543B2 (en) 2013-08-13
AU2010217629A1 (en) 2011-09-15
KR20110128896A (ko) 2011-11-30
PL2401270T3 (pl) 2014-03-31
CN102388039B (zh) 2015-07-15
US20100216860A1 (en) 2010-08-26
PT2401270E (pt) 2014-01-20
EP2401270B1 (en) 2013-10-16
AU2016203684A1 (en) 2016-06-23
US8304446B2 (en) 2012-11-06
US8357716B2 (en) 2013-01-22
RS53133B (sr) 2014-06-30
HK1159621A1 (en) 2012-08-03
CA2753337A1 (en) 2010-09-02
MX2011008972A (es) 2011-12-14
SG173768A1 (en) 2011-09-29
IL214655A0 (en) 2011-09-27
JP5520969B2 (ja) 2014-06-11
PE20120307A1 (es) 2012-04-04
BRPI1013396A2 (pt) 2016-03-29
CO6420342A2 (es) 2012-04-16
ES2439773T3 (es) 2014-01-24
CN102388039A (zh) 2012-03-21
HRP20131174T1 (hr) 2014-01-17
UY32464A (es) 2010-09-30
WO2010097395A1 (en) 2010-09-02
US20120015932A1 (en) 2012-01-19
EA021740B1 (ru) 2015-08-31
MA33132B1 (fr) 2012-03-01
US20130030031A1 (en) 2013-01-31
SI2401270T1 (sl) 2014-01-31
AR075594A1 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
CL2013002821A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; composicion farmaceutica que los comprende; y su uso como antagonista de los receptores tropomiosina (trk) para el tratamiento del dolor.
CO6680683A2 (es) Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
NZ708593A (en) Novel pyrazole derivative
EA201290655A1 (ru) Новые производные замещенного бициклического триазола в качестве модуляторов гамма-секретазы
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
MX2011009847A (es) Agentes antihelminticos y su uso.
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
UY30282A1 (es) Compuestos quimicos
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
EA201391524A1 (ru) Производные гликозида и их применение